Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.

Corrie, P; Marshall, A; Dunn, J; Middleton, M; Nathan, P; Gore, M; Davidson, N; Nicholson, S; Kelly, C; Marples, M; Danson, S; Marshall, E; Houston, S; Board, R; Waterston, A; Nobes, J; Harries, M; Kumar, S; Young, G; Lorigan, Paul C

Affiliation

Cambridge Cancer Trials Centre, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK.

Issue Date

2014-05

Metadata

Show full item record

Abstract

Bevacizumab, a monoclonal antibody that targets VEGF, has shown restricted activity in patients with advanced melanoma. We aimed to assess the role of bevacizumab as adjuvant treatment for patients with resected melanoma at high risk of recurrence. We report results from the preplanned interim analysis.

Citation

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. 2014, 15 (6):620-30 Lancet Oncol

Journal

The Lancet Oncology

URI

http://hdl.handle.net/10541/320613

DOI

10.1016/S1470-2045(14)70110-X

PubMed ID

24745696

Type

Article

Language

ISSN

1474-5488

Collections

All Christie Publications